142 related articles for article (PubMed ID: 37247109)
1. Dupilumab for Post-Hematopoietic Cell Transplantation Dermatitis in Wiskott-Aldrich Syndrome.
Adir D; Freund T; Dotan A; Mashiah J; Hagin D
J Clin Immunol; 2023 Oct; 43(7):1526-1528. PubMed ID: 37247109
[No Abstract] [Full Text] [Related]
2. Current and emerging treatment options for Wiskott-Aldrich syndrome.
Worth AJ; Thrasher AJ
Expert Rev Clin Immunol; 2015; 11(9):1015-32. PubMed ID: 26159751
[TBL] [Abstract][Full Text] [Related]
3. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
4. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
[TBL] [Abstract][Full Text] [Related]
5. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
6. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
8. One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years.
Elfeky RA; Furtado-Silva JM; Chiesa R; Rao K; Amrolia P; Lucchini G; Gilmour K; Adams S; Bibi S; Worth A; Thrasher AJ; Qasim W; Veys P
J Allergy Clin Immunol; 2018 Nov; 142(5):1654-1656.e7. PubMed ID: 30055182
[No Abstract] [Full Text] [Related]
9. The genotype of the original Wiskott phenotype.
Binder V; Albert MH; Kabus M; Bertone M; Meindl A; Belohradsky BH
N Engl J Med; 2006 Oct; 355(17):1790-3. PubMed ID: 17065640
[TBL] [Abstract][Full Text] [Related]
10. [Wiskott-Aldrich syndrome: recent progress in diagnosis and treatment].
Nonoyama S
Rinsho Ketsueki; 2009 Oct; 50(10):1570-6. PubMed ID: 19915368
[No Abstract] [Full Text] [Related]
11. Stable mixed chimerism after hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome.
Doğu F; Kurtuluş-Ulküer M; Bilge Y; Bozdoğan G; Ulküer U; Malhatun E; Ikincioğullari A; Babacan E
Pediatr Transplant; 2006 May; 10(3):395-9. PubMed ID: 16677369
[TBL] [Abstract][Full Text] [Related]
12. Six-Year Long Follow-up of Patient With Wiskott-Aldrich Syndrome Post Haploidentical Stem Cell Transplant.
Sachdev M; Chakraborty S; Bansal M; Dua V
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1252-e1253. PubMed ID: 33625090
[No Abstract] [Full Text] [Related]
13. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
Candotti F
J Clin Immunol; 2018 Jan; 38(1):13-27. PubMed ID: 29086100
[TBL] [Abstract][Full Text] [Related]
14. Medicine. Gene therapy that works.
Verma IM
Science; 2013 Aug; 341(6148):853-5. PubMed ID: 23970689
[No Abstract] [Full Text] [Related]
15. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor.
Charrier S; Blundell M; Cédrone G; Louache F; Vainchenker W; Thrasher AJ; Galy A
Haematologica; 2013 Aug; 98(8):1300-8. PubMed ID: 23445877
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy: primed for take-off.
Leboulch P
Nature; 2013 Aug; 500(7462):280-2. PubMed ID: 23955226
[No Abstract] [Full Text] [Related]
17. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.
Hacein-Bey Abina S; Gaspar HB; Blondeau J; Caccavelli L; Charrier S; Buckland K; Picard C; Six E; Himoudi N; Gilmour K; McNicol AM; Hara H; Xu-Bayford J; Rivat C; Touzot F; Mavilio F; Lim A; Treluyer JM; Héritier S; Lefrère F; Magalon J; Pengue-Koyi I; Honnet G; Blanche S; Sherman EA; Male F; Berry C; Malani N; Bushman FD; Fischer A; Thrasher AJ; Galy A; Cavazzana M
JAMA; 2015 Apr; 313(15):1550-63. PubMed ID: 25898053
[TBL] [Abstract][Full Text] [Related]
19. [HLA haploidentical hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: a case report and literatures review].
Ma H; Liu L; Xu S; Hu W; Zhang Y; Ma Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1027-9. PubMed ID: 25417886
[No Abstract] [Full Text] [Related]
20. Broadening the indications for hematopoietic stem cell genetic therapies.
Williams DA
Cell Stem Cell; 2013 Sep; 13(3):263-4. PubMed ID: 24012366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
